Tag Archives: biotechnology

3-D vaccine spontaneously assembles to pack a powerful punch against cancer, infectious diseases

“This vaccine is a wonderful example of applying biomaterials to new questions and issues in medicine,” says David Mooney, Ph.D., a professor of bioengineering at Harvard University in the School of Engineering and Applied Sciences, whose lab developed the vaccine. The project was co-led by Jaeyun Kim, Ph.D. and Aileen Li, a doctoral student in the Mooney lab. Their findings were published in the December 8, 2014 issue of Nature Biotechnology. …

Molecular breakthrough could halt spread of prostate cancer — ScienceDaily

Pioneering research, by academics at the Universities of Bristol, Nottingham and the University of the West of England (UWE Bristol), shows that a specific compound can inhibit the activity of a molecule which is key to how tumours form new blood vessels. The vessels are essential for the cancer cells to survive and multiply. The findings, published in the journal Oncogene, show that targeting a molecule called SRPK1 could stop progression of prostate cancer…

New mechanism affecting cell migration found

Cell migration has mainly been studied in cell culture environment. However, in animal tissues cells predominantly migrate in a three-dimensional environment, where they have to push through adjacent cell-layers and extracellular matrix. Migrating cells are known to form dynamic protrusions at their leading edge, but the function of these actin-rich protrusions has remained elusive. By using fruit fly as a model system, Minna Poukkula working at the Institute of Biotechnology, University of Helsinki, has found out how actin-rich protrusions contribute to cell migration in animal tissues…

Research shows early promise of new drug for cancers caused by viruses

The research team focuses on primary effusion lymphoma (PEL), an aggressive and deadly variant of diffuse large B-cell lymphoma that frequently occurs in people infected with HIV. Though scientists have known that the Kaposi’s sarcoma-associated herpesvirus (KSHV) causes PEL, development of effective therapies has proven difficult. PEL tumors arise within body cavities and progress rapidly with an average survival of around 6 months. Combination chemotherapy represents the current standard of care for PEL, but side effects (including bone marrow suppression) and drug resistance (generated through virus-associated mechanisms) continue to limit the effectiveness of standard therapy…